AJP - Endocrinology and Metabolism, Vol 268, Issue 2 E185-E193, Copyright © 1995 by American Physiological Society

ARTICLES

A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic beta-cells

M. Akiyoshi, M. Kakei, M. Nakazaki and H. Tanaka
First Department of Internal Medicine, Faculty of Medicine, Kagoshima University, Japan.

Effects of a new hypoglycemic drug, N-[trans-4-isopropylcyclohexy-carbonyl]-D-phenylalanine (A-4166), on membrane current were investigated using the patch-clamp technique in single pancreatic beta-cells isolated from rats. A-4166, at a concentration of 10 microM, depolarized membrane potential of beta-cells and evoked action potentials in the presence of 2.8 mM glucose. The single ATP-sensitive K+ channel (K-ATP channel) current recorded in cell-attached membrane patches was reversibly inhibited by A-4166 (> 0.1 microM) without a change in the single-channel conductance of the K-ATP channel. Both A-4166 and tolbutamide inhibited the whole cell K-ATP channel current with half-maximum inhibition (IC50) of 0.23 and 12.8 microM, respectively (Hill coefficient = 1). In inside-out membrane patches, the IC50 with A-4166 occurred at 4.5 nM, in contrast to 0.7 microM for tolbutamide. A-4166 did not affect L- and T-type Ca2+ channels or the time-dependent outward current. We conclude that A-4166 specifically blocks the K-ATP channel and that the blockade is more potent than that of tolbutamide. The action of A-4166 underlies the mechanism by which the drug stimulates insulin secretion from beta-cells.

This article has been cited by other articles:

				M. Chachin, M. Yamada, A. Fujita, T. Matsuoka, K. Matsushita, and Y. Kurachi Nateglinide, a D-Phenylalanine Derivative Lacking Either a Sulfonylurea or Benzamido Moiety, Specifically Inhibits Pancreatic beta -Cell-Type KATP Channels J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1025 - 1032. [Abstract] [Full Text] [PDF]

				F. M. Gribble, S. E. Manley, and J. C. Levy Randomized Dose Ranging Study of the Reduction of Fasting and Postprandial Glucose in Type 2 Diabetes by Nateglinide (A-4166) Diabetes Care, July 1, 2001; 24(7): 1221 - 1225. [Abstract] [Full Text] [PDF]

				N. Itabashi, K. Okada, S. Muto, N. Fujita, T. Ohta, J.-i. Miyazaki, Y. Asano, and T. Saito A Novel Enhancer of Insulinotrophic Action by High Glucose (JTT-608) Stimulates Insulin Secretion from Pancreatic beta -Cells via a New Cellular Mechanism J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 953 - 960. [Abstract] [Full Text]

				S. Hashiguchi, T. Yada, and T. Arima A New Hypoglycemic Agent, JTT-608, Evokes Protein Kinase A-Mediated Ca2+ Signaling in Rat Islet {beta}-Cells: Strict Regulation by Glucose, Link to Insulin Release, and Cooperation with Glucagon-Like Peptide-1(7-36)amide and Pituitary Adenylate Cyclase-Activating Polypeptide J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 22 - 30. [Abstract] [Full Text]

				S. Hu, S. Wang, B. Fanelli, P. A. Bell, B. E. Dunning, S. Geisse, R. Schmitz, and B. R. Boettcher Pancreatic beta -Cell KATP Channel Activity and Membrane-Binding Studies with Nateglinide: A Comparison with Sulfonylureas and Repaglinide J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 444 - 452. [Abstract] [Full Text]

				S. Hu, S. Wang, and B. E. Dunning Tissue Selectivity of Antidiabetic Agent Nateglinide: Study on Cardiovascular and beta -Cell KATP Channels J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1372 - 1379. [Abstract] [Full Text]